169 related articles for article (PubMed ID: 24481415)
1. The prognostic value of midregional proatrial natriuretic peptide in patients with hemorrhagic stroke.
Fischer M; Katan M; Morgenthaler NG; Seiler M; Müller B; Lackner P; Errath M; Helbok R; Pfausler B; Beer R; Schmutzhard E; Broessner G
Cerebrovasc Dis; 2014; 37(2):128-33. PubMed ID: 24481415
[TBL] [Abstract][Full Text] [Related]
2. Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke.
Katan M; Fluri F; Schuetz P; Morgenthaler NG; Zweifel C; Bingisser R; Kappos L; Steck A; Engelter ST; Müller B; Christ-Crain M
J Am Coll Cardiol; 2010 Sep; 56(13):1045-53. PubMed ID: 20846604
[TBL] [Abstract][Full Text] [Related]
3. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
4. Midregional proatrial natriuretic peptide predicts survival in exacerbations of COPD.
Bernasconi M; Tamm M; Bingisser R; Miedinger D; Leuppi J; Müller B; Christ-Crain M; Stolz D
Chest; 2011 Jul; 140(1):91-99. PubMed ID: 21106656
[TBL] [Abstract][Full Text] [Related]
5. MR-proANP improves prediction of mortality and cardiovascular events in patients with STEMI.
Lindberg S; Jensen JS; Pedersen SH; Galatius S; Goetze JP; Mogelvang R
Eur J Prev Cardiol; 2015 Jun; 22(6):693-700. PubMed ID: 24906365
[TBL] [Abstract][Full Text] [Related]
6. Midregional proatrial natriuretic peptide improves risk stratification after ischemic stroke.
De Marchis GM; Schneider J; Weck A; Fluri F; Fladt J; Foerch C; Mueller B; Luft A; Christ-Crain M; Arnold M; Katan M
Neurology; 2018 Feb; 90(6):e455-e465. PubMed ID: 29321236
[TBL] [Abstract][Full Text] [Related]
7. Outcome prediction and temperature dependency of MR-proANP and Copeptin in comatose resuscitated patients.
Broessner G; Hasslacher J; Beer R; Lackner P; Lehner GF; Harler U; Schiefecker A; Helbok R; Pfausler B; Hammerer-Lercher A; Joannidis M
Resuscitation; 2015 Apr; 89():75-80. PubMed ID: 25619444
[TBL] [Abstract][Full Text] [Related]
8. MR-pro-atrial natriuretic peptide (MR-proANP) predicts short- and long-term outcomes in respiratory tract infections: a prospective validation study.
Vazquez M; Jockers K; Christ-Crain M; Zimmerli W; Müller B; Schuetz P
Int J Cardiol; 2012 Apr; 156(1):16-23. PubMed ID: 21093937
[TBL] [Abstract][Full Text] [Related]
9. Blood-based microcirculation markers in Alzheimer's disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio.
Buerger K; Ernst A; Ewers M; Uspenskaya O; Omerovic M; Morgenthaler NG; Knauer K; Bergmann A; Hampel H
Biol Psychiatry; 2009 Jun; 65(11):979-84. PubMed ID: 19344890
[TBL] [Abstract][Full Text] [Related]
10. Midregional pro-A-type natriuretic peptide for diagnosis and prognosis in patients with suspected acute myocardial infarction.
Meune C; Twerenbold R; Drexler B; Balmelli C; Wolf C; Haaf P; Reichlin T; Irfan A; Reiter M; Zellweger C; Meissner J; Stelzig C; Freese M; Capodarve I; Mueller C
Am J Cardiol; 2012 Apr; 109(8):1117-23. PubMed ID: 22257708
[TBL] [Abstract][Full Text] [Related]
11. Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study.
Daniels LB; Clopton P; Potocki M; Mueller C; McCord J; Richards M; Hartmann O; Anand IS; Wu AH; Nowak R; Peacock WF; Ponikowski P; Mockel M; Hogan C; Filippatos GS; Di Somma S; Ng L; Neath SX; Christenson R; Morgenthaler NG; Anker SD; Maisel AS
Eur J Heart Fail; 2012 Jan; 14(1):22-31. PubMed ID: 22140234
[TBL] [Abstract][Full Text] [Related]
12. Increased plasma concentrations of midregional proatrial natriuretic Peptide is associated with risk of cardiorenal dysfunction in type 1 diabetes.
Theilade S; Hansen TW; Goetze JP; Rossing P
Am J Hypertens; 2015 Jun; 28(6):772-9. PubMed ID: 25468806
[TBL] [Abstract][Full Text] [Related]
13. Mid-regional pro-atrial natriuretic peptide as a prognostic marker for all-cause mortality in patients with symptomatic coronary artery disease.
von Haehling S; Papassotiriou J; Hartmann O; Doehner W; Stellos K; Geisler T; Wurster T; Schuster A; Botnar RM; Gawaz M; Bigalke B
Clin Sci (Lond); 2012 Nov; 123(10):601-10. PubMed ID: 22690794
[TBL] [Abstract][Full Text] [Related]
14. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia.
Masiá M; Papassotiriou J; Morgenthaler NG; Hernández I; Shum C; Gutiérrez F
Clin Chem; 2007 Dec; 53(12):2193-201. PubMed ID: 17951293
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure.
Seronde MF; Gayat E; Logeart D; Lassus J; Laribi S; Boukef R; Sibellas F; Launay JM; Manivet P; Sadoune M; Nouira S; Solal AC; Mebazaa A;
Int J Cardiol; 2013 Oct; 168(4):3404-11. PubMed ID: 23684562
[TBL] [Abstract][Full Text] [Related]
16. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.
Elmas E; Brueckmann M; Lang S; Kälsch T; Haghi D; Sueselbeck T; Dempfle CE; Borggrefe M
Int J Cardiol; 2008 Aug; 128(2):244-9. PubMed ID: 17673312
[TBL] [Abstract][Full Text] [Related]
17. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
Maisel A; Mueller C; Nowak R; Peacock WF; Landsberg JW; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand I; Ng L; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Terracciano G; Kremastinos D; Hartmann O; von Haehling S; Bergmann A; Morgenthaler NG; Anker SD
J Am Coll Cardiol; 2010 May; 55(19):2062-76. PubMed ID: 20447528
[TBL] [Abstract][Full Text] [Related]
18. CT-proAVP (copeptin), MR-proANP and Peroxiredoxin 4 after cardiac arrest: release profiles and correlation to outcome.
Annborn M; Dankiewicz J; Nielsen N; Rundgren M; Smith JG; Hertel S; Struck J; Friberg H
Acta Anaesthesiol Scand; 2014 Apr; 58(4):428-36. PubMed ID: 24617620
[TBL] [Abstract][Full Text] [Related]
19. Dysnatremia, vasopressin, atrial natriuretic peptide and mortality in patients with community-acquired pneumonia: results from the german competence network CAPNETZ.
Krüger S; Ewig S; Giersdorf S; Hartmann O; Frechen D; Rohde G; Suttorp N; Welte T;
Respir Med; 2014 Nov; 108(11):1696-705. PubMed ID: 25306251
[TBL] [Abstract][Full Text] [Related]
20. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36).
O'Malley RG; Bonaca MP; Scirica BM; Murphy SA; Jarolim P; Sabatine MS; Braunwald E; Morrow DA
J Am Coll Cardiol; 2014 Apr; 63(16):1644-53. PubMed ID: 24530676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
